Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

vTv Therapeutics (VTVT) Equity Average: 2015-2025

Historic Equity Average for vTv Therapeutics (VTVT) over the last 10 years, with Sep 2025 value amounting to $36.7 million.

  • vTv Therapeutics' Equity Average rose 91.15% to $36.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $36.7 million, marking a year-over-year increase of 91.15%. This contributed to the annual value of -$5.2 million for FY2024, which is 70.70% up from last year.
  • Latest data reveals that vTv Therapeutics reported Equity Average of $36.7 million as of Q3 2025, which was up 528.74% from $5.8 million recorded in Q2 2025.
  • vTv Therapeutics' Equity Average's 5-year high stood at $36.7 million during Q3 2025, with a 5-year trough of -$68.2 million in Q1 2021.
  • Moreover, its 3-year median value for Equity Average was $5.8 million (2025), whereas its average is $2.3 million.
  • Its Equity Average has fluctuated over the past 5 years, first plummeted by 167.62% in 2023, then skyrocketed by 1,674.90% in 2025.
  • Quarterly analysis of 5 years shows vTv Therapeutics' Equity Average stood at -$15.6 million in 2021, then increased by 12.71% to -$13.7 million in 2022, then crashed by 82.77% to -$25.0 million in 2023, then surged by 164.54% to $16.1 million in 2024, then surged by 91.15% to $36.7 million in 2025.
  • Its Equity Average stands at $36.7 million for Q3 2025, versus $5.8 million for Q2 2025 and $11.6 million for Q1 2025.